Picture an earnings call where one question keeps looping: can two fast-growing immunology drugs really replace a mega-blockbuster that defined a decade of pharma profits? That’s the AbbVie s
Picture an earnings call where one question keeps looping: can two fast-growing immunology drugs really replace a mega-blockbuster that defined a decade of pharma profits? That’s the AbbVie story in a sentence.
Portfolio managers now model every quarter around the same pivot: Humira is sliding post-biosimilars; Skyrizi and Rinvoq are sprinting. The gap is the whole ballgame.
If you care about cash flow durability, margins, and what happens when a moat meets generics, this is the stack to watch.
Humira’s patent exclusivity broke in Europe years ago and in the U.S. in 2023, opening the door to a swarm of adalimumab biosimilars. That forced AbbVie to do what every big pharma hopes it never has to do: rebuild the core from inside. The plan is clear enough. Let Humira decline at a managed pace while Skyrizi (risankizumab, an IL‑23 inhibitor) and Rinvoq (upadacitinib, a selective JAK inhibitor) scale across dermatology, rheumatology, and gastroenterology.
AbbVie’s earnings hinge on a handoff: defend Humira’s base just long enough for Skyrizi and Rinvoq to reach escape velocity across multiple indications and geographies.
Why now? Because post‑loss‑of‑exclusivity curves don’t wait. Payers re-tier. Net prices reset. Prescribers experiment. Patients ask about cheaper options. The company either backfills revenue fast or the P&L re-rates.
Humira was the archetypal mega‑blockbuster: multiple autoimmune indications, years of IP layers, and a massive commercial engine. But time always wins. Europe saw biosimilars earlier, and the U.S. followed in 2023 as a pack of adalimumab copies arrived, including interchangeable versions like Cyltezo, validated at the agency level by the FDA years prior (FDA).
The erosion mechanics are familiar. You get a stair‑step decline as contracts renew, formularies shift, and net price blends compress. The question for investors isn’t whether Humira declines. It’s the slope of the line and whether new revenue can outrun it.
Skyrizi and Rinvoq weren’t accidents. AbbVie designed them to cover broad autoimmune ground, with mechanisms that fit the current standard of care debates: targeted cytokine inhibition for Skyrizi; a potent but selective JAK for Rinvoq. Each one has stacked indications over time as data matured and regulators weighed in.
Skyrizi first broke through in moderate to severe plaque psoriasis, then gathered momentum in psoriatic arthritis and inflammatory bowel disease as data landed. U.S. labels reflect that breadth today, spanning psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (AbbVie Prescribing Information).
Rinvoq started in rheumatoid arthritis and has since expanded into atopic dermatitis, psoriatic arthritis, ankylosing spondylitis/axial spondyloarthritis, ulcerative colitis, and Crohn’s disease, among others, following rigorous clinical programs and risk‑benefit reviews (AbbVie Prescribing Information).
Those expansions matter. Each new indication extends the total addressable market, allows multi‑specialty detailing, and opens new payer contracts. It’s the difference between a niche therapy and a platform franchise.
Market access is the unglamorous engine here. With Humira facing cheaper biosimilars, payers pressure the class on price. But payers and prescribers also value clinical differentiation: dosing convenience, durable response, and safety profiles adapted to long‑term use. That’s where Skyrizi’s IL‑23 story and Rinvoq’s efficacy in difficult‑to‑treat populations give AbbVie real talking points.
It’s rarely linear, though. Prior authorization, step therapy, and rebates can make uptake lumpy quarter to quarter. And for Rinvoq, JAK class scrutiny means more paperwork and careful patient selection, even with selective targeting and extensive safety data baked into labels and REMS where relevant.
Across recent quarters, the pattern has been pretty consistent: Humira down as expected post‑U.S. biosimilars, while Skyrizi and Rinvoq post strong year‑over‑year growth and sequential gains. Management has repeatedly framed the pair as the company’s primary growth engine and has suggested, in public remarks and investor materials, that they’re positioned to ultimately surpass Humira’s contribution over time, assuming continued execution and label breadth (AbbVie IR).
It’s worth remembering this isn’t just a sales contest. Skyrizi and Rinvoq sell into categories where outcome measures are getting sharper. Dermatology values clear skin rates and durability. GI cares about histologic remission and steroid‑free maintenance. Rheumatology tracks function and flares. AbbVie’s trials have been built around those endpoints, which is central to prescribing behavior and payer decisions.
Franchise Mechanism Key Indications (US) Administration Competitive Set Commercial Notes Humira (adalimumab) TNF inhibitor Multiple autoimmune (legacy) Subcutaneous TNF class + many biosimilars Net price compression after 2023 U.S. biosimilar entry; high brand recognition Skyrizi (risankizumab) IL‑23 inhibitor Psoriasis, PsA, Crohn’s, UC Subcutaneous; IV induction in GI IL‑23/IL‑17/IL‑12/23 rivals Strong skin clearance profile; convenient maintenance dosing; expanding GI footprint Rinvoq (upadacitinib) Selective JAK RA, AD, PsA, AS/axSpA, UC, Crohn’s Oral, once daily JAKs and targeted biologics High efficacy in difficult disease; class safety monitoring and labeling influence access
Regulatory context supports the breadth. U.S. approvals for Skyrizi in psoriasis came first, then psoriatic arthritis and GI indications as data matured; Rinvoq’s initial RA approval extended into dermatology and IBD following robust phase 3 programs and further safety label updates along the way (FDA Approvals Database).
Let’s talk math. Humira’s contribution was never just volume. It was margin heft from a mature brand with optimized manufacturing and a long tail of loyal prescribers. Replacing that is about volume and mix. Net prices in immunology are pressured by biosimilars on one side and rival brands on the other. AbbVie can’t ignore either.
Skyrizi competes in a crowded biologics space where IL‑23s and IL‑17s have real followings. The pitch is efficacy, dosing convenience, and durability. In GI, it also faces anti‑integrins and other targeted mechanisms. That’s healthy competition, but it means share gains are earned, not gifted.
Rinvoq competes against other JAKs and against biologics favored by certain payers for safety familiarity. The JAK class has had higher regulatory scrutiny, including boxed warnings and post‑marketing requirements, which shape prescriber comfort and payer criteria. That doesn’t preclude growth; it just requires relentless data generation and precise positioning.
Biosimilars pull reference pricing down across categories, even if not directly substitutable. Expect continuing negotiation cycles as large PBMs and plans attempt to capture savings. For AbbVie, the lever is differentiation proven in head‑to‑head or meaningful indirect comps, plus label expansions that unlock broader contracts.
Friction matters. Skyrizi’s maintenance schedule is a selling point for adherence. Rinvoq’s oral dosing is patient‑friendly. But reliability, supply continuity, and support programs can be tie‑breakers. AbbVie has scale, which helps. It still needs to keep fulfillment boringly predictable.
If you want to know whether Skyrizi and Rinvoq can fully replace Humira, track a handful of concrete milestones and signals.
Replacement isn’t a single quarter event; it’s a sequence of flawless quarters. A wobble in access, safety, or pricing can push the crossover further out.
If you want a steady drumbeat on how immunology franchises are trending around earnings season, I keep an eye on company filings and primary sources. For broader market color and how biotech intersects with risk appetite across assets, I also read outlets like Crypto Daily to see how flows and sentiment are shifting at the macro level. Different market, same discipline: watch the data, ignore the noise.
They’re positioned to backfill revenue and profit that AbbVie historically drew from Humira, a top‑selling anti‑TNF biologic that’s now under intense biosimilar pressure in the U.S. and already faced it in Europe. The replacement goal is financial, not therapeutic one‑for‑one.
Humira targets TNF, a broad inflammatory cytokine. Skyrizi selectively inhibits IL‑23, which has shown strong skin and GI outcomes. Rinvoq is a selective JAK inhibitor, oral and potent, affecting intracellular signaling pathways. Different mechanisms, overlapping disease areas.
Management has suggested the combination is positioned to overtake Humira’s contribution over time as labels expand and access improves, but exact timing depends on uptake, pricing, and competition. Watch consecutive quarters of double‑digit growth and commentary from AbbVie IR for clues.
Payer controls like step therapy and prior authorization, prescriber caution around JAK class safety for Rinvoq, and competition from other biologics in dermatology, rheumatology, and GI. Supply reliability and patient support programs also influence real‑world uptake.
Indirectly. Cheaper adalimumab options push down immunology net price expectations. That can make payers tougher negotiators across the board. Still, if clinical differentiation is clear, premium brands can keep favorable access and share.
Year‑over‑year and sequential sales growth for Skyrizi and Rinvoq, Humira decline slope, commentary on formulary wins, any label updates, and margin trends. Also note any safety communications or manufacturing updates in press releases or filings.
Check the FDA’s approvals and labeling database for official updates (FDA) and the current U.S. Prescribing Information for Skyrizi and Rinvoq provided by AbbVie (Skyrizi PI; Rinvoq PI).
Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
